Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of precision therapeutics for patients with cancer. Founded in 2018 and based in Cambridge, Massachusetts, Kronos Bio applies its proprietary functional genomics platform to identify and validate vulnerabilities in transcriptional and epigenetic regulation that drive tumor growth. By integrating advanced screening technologies, the company aims to accelerate target identification and optimize small-molecule drug candidates with high potency and selectivity.
The company’s lead programs focus on selective inhibitors of cyclin-dependent kinase 9 (CDK9), a critical regulator of gene expression in cancer cells, and novel modulators of transcriptional machinery that have demonstrated the potential to overcome resistance mechanisms associated with existing therapies. Kronos Bio’s pipeline includes clinical-stage candidates that have entered early-phase studies in the United States, with plans to expand into European centers to evaluate safety, pharmacodynamics and preliminary efficacy in multiple hematological and solid tumor indications.
Kronos Bio’s research and development efforts are supported by a team of experienced industry leaders and scientific founders with deep expertise in oncology drug discovery and translational medicine. The leadership team is committed to advancing a disciplined clinical strategy, leveraging biomarker-driven patient selection to maximize therapeutic benefit and inform subsequent trial design. Strategic collaborations with academic institutions and contract research organizations enable Kronos Bio to maintain flexibility in resource allocation while driving programs toward key value-inflection milestones.
With a focus on precision oncology and a growing clinical portfolio, Kronos Bio is positioned to address high unmet medical needs in cancer treatment. The company’s approach reflects an emphasis on rigorous target validation, translational research and biomarker development, all aimed at delivering innovative therapies that can improve long-term outcomes for patients facing aggressive malignancies.
AI Generated. May Contain Errors.
